CV Sciences (CVSI) Return on Capital Employed (2011 - 2026)
CV Sciences (CVSI) reported Return on Capital Employed of 48.07% for Q1 2026, up 1207.0% on a YoY basis from 3.68% in Q1 2025, and down 102.37% sequentially from 23.76% in Q4 2025.
CV Sciences (CVSI) Return on Capital Employed (2011 - 2026) Analysis & Trends
CV Sciences (CVSI) has 16 years of Return on Capital Employed data on file, last reported at 48.07% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 1207.0% year-over-year to 48.07%; the trailing twelve-month figure through Mar 2026 stood at 48.07% (up 1207.0% YoY), and the FY2025 full-year result was 19.23%, up 7000.0% from the prior year.
- Return on Capital Employed fell to 48.07% in Q1 2026, from 23.76% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 159.07% in Q3 2024 to a low of 1062.37% in Q4 2022.
- A 5-year average of 152.52% and a median of 48.07% in 2026 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed sank 77312 bps in 2022 and surged 116399 bps in 2023, its largest moves.
- Tracing CVSI's Return on Capital Employed over 5 years: stood at 1062.37% in 2022, then jumped by 110 bps to 101.62% in 2023, then grew by 9 bps to 110.89% in 2024, then plunged by 121 bps to 23.76% in 2025, then plunged by 102 bps to 48.07% in 2026.
- Business Quant data shows CVSI's Return on Capital Employed at 48.07% in Q1 2026, 23.76% in Q4 2025, and 38.75% in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | CV Sciences | 3.74 Mn | 3.43 Mn | 1.56 Mn | -48.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -48.07% |
| Dec 31, 2025 | -23.76% |
| Sep 30, 2025 | -38.75% |
| Jun 30, 2025 | -51.48% |
| Mar 31, 2025 | -60.15% |
| Dec 31, 2024 | 110.89% |
| Sep 30, 2024 | 159.07% |
| Jun 30, 2024 | -95.61% |
| Mar 31, 2024 | -105.15% |
| Dec 31, 2023 | 101.62% |
| Sep 30, 2023 | 57.41% |
| Jun 30, 2023 | 34.59% |
| Mar 31, 2023 | 7.35% |
| Dec 31, 2022 | -1,062.37% |
| Sep 30, 2022 | -701.21% |
| Jun 30, 2022 | -452.92% |
| Mar 31, 2022 | -424.28% |
| Dec 31, 2021 | -289.26% |
| Sep 30, 2021 | -142.30% |
| Jun 30, 2021 | -131.04% |